Clinical Trials Logo

Cerebral Hemorrhage clinical trials

View clinical trials related to Cerebral Hemorrhage.

Filter by:

NCT ID: NCT05630534 Not yet recruiting - Clinical trials for Intracerebral Hemorrhage

Minocycline Accelerates Intracerebral Hemorrhage Absorption

MACHA
Start date: January 1, 2023
Phase: Phase 1
Study type: Interventional

Minocycline has been found to reduce cerebral edema secondary to cerebral hemorrhage, promote hematoma absorption, and shorten hematoma absorption time; clinical studies have been conducted to confirm the safety in the treatment, but no significant hematoma absorption effect was seen with short duration of drug use. Therefore, the investigators propose to conduct a multicenter randomized controlled clinical trial to determine its accelerating effect on hematoma absorption.

NCT ID: NCT05620810 Not yet recruiting - Clinical trials for Primary Disease or Condition Being Studied, or Focus of the Study

Neuropsychiatric Symptoms in Spontaneous Intracerebral Hemorrhage Survivors

Start date: January 1, 2023
Phase:
Study type: Observational

Compared to the United Kingdom and the United States, Spontaneous non-traumatic intracerebral hemorrhage (ICH) is more common among people in Taiwan. The prevalence rate of ICH was 14.0% for people aged 36 years or older in Taiwan. Primary ICH originates from the spontaneous rupture of small vessels damaged by chronic hypertension or cerebral amyloid angiopathy (CAA). Emotional disturbances are frequent symptoms in stroke survivors and negatively impact on functional recovery, the patient's quality of life and are distressing for both the patients and their caregivers. Furthermore, the emotional disturbances are associated with impaired cognitive. However, these issues are often unnoticed and most of the studies had been performed in ischemic stroke survivors rather than in patients with ICH. In this study, we will be recruited participants from National Taiwan University Hospital Bei-Hu branch and National Taiwan University Hospital. We aim to enroll respectively maximum number of 60 patients who had previous spontaneous ICH. Each participant will receive neuropsychiatric assessment, cognitive screening tests, domain-specific cognitive tests, a questionnaire for their quality of life and blood drawing for ApoE genotyping. The main aims of this study include (1) To investigate the prevalence of distinct neuropsychiatric symptoms in ICH survivors (2) To investigate the impact of non-cognitive neuropsychiatric issues on the cognitive functions and quality of life in ICH survivors. Our results may remind clinicians to pay more attention to the early diagnosis and effective management of neuropsychiatric symptoms to improve clinical outcomes.

NCT ID: NCT05593380 Not yet recruiting - Critical Care Clinical Trials

The Effect of BIA Monitoring of Brain Edema on the Neurological Prognosis of Supratentorial Massive ICH

BIATICH
Start date: October 15, 2022
Phase: N/A
Study type: Interventional

Spontaneous cerebral hemorrhage (SICH) is a hemorrhage caused by the rupture of a blood vessel within the brain parenchyma that is non-traumatic. Its rapid onset and dangerous condition seriously threaten human health; it accounts for about 15% of strokes and 50% of stroke-related mortality. Hunan Province is recognized as one of the high incidence areas of cerebral hemorrhage in the world; according to statistics, the direct economic loss caused by cerebral hemorrhage in Hunan Province is more than 1 billion yuan per year, which should be paid great attention. A 30-day follow-up study of large-volume cerebral hemorrhage (defined as supratentorial hemorrhage greater than 30 ml, infratentorial greater than 5 ml, and thalamus and cerebellum greater than 15 ml) found that the morbidity and mortality rate of ICH with hemorrhage of 30-60 ml was as high as 44-74%, while the morbidity and mortality rate of ICH with hemorrhage of <30 ml was 19% and that of >60 ml was 91%. According to studies, the occurrence of hematoma occupancy and malignant cerebral edema in large-volume cerebral hemorrhage can lead to secondary malignant intracranial pressure elevation and subsequent secondary brain injury, which are the main factors of high morbidity and mortality and poor prognosis in patients with large-volume cerebral hemorrhage. Clinical monitoring and management is the key to treatment, and despite aggressive surgical treatment and anti-brain edema therapy, a large number of patients progress to malignant brain edema disease, leading to poor outcomes. Therefore, this project intends to conduct a multicenter clinical trial of non-invasive monitoring of large volume cerebral hemorrhage on the curtain in the Hunan region to explore the impact of non-invasive brain edema monitoring management based on bioelectrical impedance technology on patient prognosis; and to explore early biomarkers of malignant brain edema through metabolomic analysis and the mechanism of malignant brain edema occurrence through multi-omic analysis to provide data support for the clinical treatment application of malignant brain edema.

NCT ID: NCT05502874 Not yet recruiting - Hemorrhage Clinical Trials

Multicenter Registry for Assessment of Markers of Early Neurological Deterioration in Primary Intracerebral Hemorrhage

CATCH
Start date: September 1, 2022
Phase:
Study type: Observational

This multicenter observational study will explore the risk factors of early neurological deterioration(END) in patients with primary and to investigate the association between END and outcome.

NCT ID: NCT05263167 Not yet recruiting - Edema Brain Clinical Trials

Reducing Edema After intraCerebral Hemorrhage

Start date: March 15, 2022
Phase: Phase 4
Study type: Interventional

The REACH trial is a prospective multicenter double-blind randomized placebo-controlled trial with blinded end-point adjudication. Participants are randomized (1:1) to receive either sodium aescinate or matching placebo (0.9% saline). The primary outcome is the absolute volume of PHE evaluated based on brain CT image on day 14 after ICH.

NCT ID: NCT05158660 Not yet recruiting - Clinical trials for Intracerebral Hematoma

Assessment of Intracerebral Hematoma

Start date: January 2022
Phase: N/A
Study type: Interventional

The study will assess acute intracerebral hematoma expansion within the first 48 hours from the onset using transcranial duplex sonography in patients who have acute intracerebral hematoma , and will also assess the correlation between the transcranial duplex sonography measurements and the clinical outcome of these patients .

NCT ID: NCT05066620 Not yet recruiting - Clinical trials for Intracerebral Hemorrhage

Chinese Herbal Medicine in Acute INtracerebral Haemorrhage (CHAIN) Trial

Start date: October 2021
Phase: Phase 3
Study type: Interventional

TCM is an essential context of the ICH management in Chinese culture. Given the potential benefits of Chinese herbal medicine FYTF-919 in reducing haematoma and bleeding after acute ICH from fundamental research and small clinical studies, more reliable evidence is required to guide ICH treatment using TCM. This study aims to determine the effectiveness and safety of TCM in a larger sample of patients with moderate-severe ICH and provide evidence for TCM clinical guidelines on ICH management. The presumed mechanism of action is in promoting the reabsorption of the haematoma and perihematomal oedema in ICH.

NCT ID: NCT05051488 Not yet recruiting - Stroke, Acute Clinical Trials

Dynamic Decompressive Craniotomy

Start date: April 30, 2022
Phase:
Study type: Observational

Prospective observational study on patients undergoing decompressive craniotomy

NCT ID: NCT04957862 Not yet recruiting - Clinical trials for Hypertensive Intracerebral Hemorrhage

Robotic Assisted Evacuation of Subacute and Chronic Supratentorial Deep Hypertensive Intracerebral Hemorrhage

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

Robotic Assisted Evacuation of Subacute and Chronic Supratentorial Deep Hypertensive Intracerebral Hemorrhage for Accelerating Functional Rehabilitation (RESCUE-CHAIN): a Multi-center Randomized Controlled Trial

NCT ID: NCT04957849 Not yet recruiting - Clinical trials for Hypertensive Intracerebral Hemorrhage

Acute Hypertensive Cerebral Hemmorrhage Surgery

NET-OCEAN
Start date: January 1, 2022
Phase: N/A
Study type: Interventional

The Neuroendoscopic, Trans-occipital Approach Evacuation of Acute Hypertensive Cerebral Hemmorrhage Combined Low-drainage Surgery: a Multi-center Clinical Trial